Application of circular RNA (Ribonucleic Acid) or overexpression reagent thereof in preparation of product for preventing and / or treating heart disease
Through overexpression reagents of circRNA, especially circ-CHACR, the side effects and risks in the treatment of cardiac hypertrophy and cardiac dysfunction are solved, the inhibition of myocardial hypertrophy and the improvement of cardiac function is achieved, and new diagnostic and therapeutic methods are provided. .
Patent Information
- Application Number
- CN202411100241.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-22
AI Technical Summary
Existing treatments for myocardial hypertrophy, myocardial fibrosis and cardiac dysfunction have side effects and poor treatment effects, especially drug treatments may lead to hypotension and renal impairment, high risk of surgical treatment and donor heart shortage.
Circular RNA (circRNA) or its overexpression agent, especially circ-CHACR, inhibit cardiomyocyte hypertrophy and fibrosis through lentivirus or vectors, and early diagnosis and evaluation of heart disease risk is performed by detecting their expression levels.
It significantly inhibits cardiomyocyte hypertrophy, improves cardiac function, and improves the heart's ability to pump blood, providing a new and safe method to treat heart disease, and enhances the timeliness and accuracy of treatment.
Smart Images

Figure CN118987018A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of heart disease prevention, treatment and diagnosis, and in particular relates to the use of circular RNA or an overexpression agent thereof in the preparation of a product for preventing and / or treating heart disease. Background Art
[0002] In recent years, the morbidity and mortality of cardiovascular diseases have been on the rise, seriously affecting human health. Because of its difficult prevention and treatment, it is considered by modern medicine to be one of the main causes of human death. Therefore, preventing and / or diagnosing heart disease remains a major task in medicine and biology.
[0003] Myocardial hypertrophy is initially an adaptive response to cardiac stress, which is beneficial for maintaining cardiac function and has a protective effect. However, pathological myocardial hypertrophy is usually accompanied by a series of adverse cardiovascular events, including myocardial infarction, heart failure, etc., and may even lead to sudden death. In patients with heart disease, cardiac fibrosis and cardiac dysfunction are important indicators for predicting poor prognosis, and their severity is associated with increased rates of hospitalization, mortality, and adverse cardiac events. The incidence of heart failure has increased year by year in recent years and is still the main factor in the morbidity and mortality of cardiovascular diseases. Due to the limited options for the treatment of heart failure, inhibiting myocardial hypertrophy, myocardial fibrosis, and cardiac dysfunction is beneficial for blocking the transformation of myocardial hypertrophy, myocardial fibrosis, and cardiac dysfunction to heart failure, which is of great significance for the treatment of myocardial hypertrophy, myocardial fibrosis, cardiac dysfunction, and heart failure.
[0004] At present, the treatment for patients with myocardial hypertrophy, myocardial fibrosis, cardiac dysfunction and heart failure mainly focuses on conservative treatment, drug therapy, surgical treatment, etc. Conservative treatment mainly relieves the burden on the heart through self-control of diet, proper exercise, etc., and is mainly used to prevent the occurrence and further development of cardiovascular diseases, and it is difficult to maintain long-term treatment effects. Drug treatment mainly improves cardiac function through beta-blockers, ACE inhibitors, ARB drugs, etc., but long-term use may cause side effects such as hypotension and renal damage. Surgical treatment mainly treats heart failure through surgical correction, heart transplantation, etc., with high risks, lack of donor hearts, and is subject to many restrictions such as immune rejection. Therefore, it is crucial to develop a safe and effective drug for the diagnosis and / or prevention and treatment of diseases such as myocardial hypertrophy, myocardial fibrosis, and cardiac dysfunction.
[0005] Circular RNA (circRNA), referred to as circRNA, is a type of non-coding RNA produced by reverse splicing of one or several exons during the splicing process of precursor mRNA (pre-mRNA). It does not contain a 5' cap structure and a 3' polyadenylic acid tail structure. Its unique circular structure shows higher stability than linear RNA and is not affected by nucleases, which has great therapeutic potential. Functionally, circRNA can play a regulatory role as a miRNA sponge and a protein sponge at the same time. At present, there are no reports on the use of circRNA as a target for the diagnosis, prevention, or assessment of the risk of heart disease. Summary of the invention
[0006] In view of this, the object of the present invention is to provide a use of a circular RNA or an overexpression agent thereof in the preparation of a product for preventing and / or treating heart disease.
[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0008] The present invention provides an application of a circular RNA or an overexpression agent thereof in preparing a product for preventing and / or treating heart disease. The nucleotide sequence of the circular RNA is shown in SEQ ID No. 1, and the circular RNA is named circ-CHACR.
[0009] Preferably, the heart disease includes one or more of myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction; the circular RNA overexpression reagent includes a circ-CHACR overexpression lentivirus or a circ-CHACR overexpression vector.
[0010] The present invention provides an application of a reagent for detecting the expression level of the above-mentioned circular RNA in the preparation of a product for diagnosing or evaluating the risk of heart disease.
[0011] Preferably, the product comprises a substance capable of binding to cDNA of circular RNA; and the heart disease comprises one or more of myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction.
[0012] Preferably, the product includes one or more of a kit, a test strip, and a gene chip.
[0013] Preferably, the product comprises a primer set capable of specifically amplifying cDNA of circular RNA.
[0014] Preferably, the substance comprises a cDNA-specific probe for detecting circular RNA.
[0015] Preferably, the nucleotide sequence of the primer set is shown in SEQ ID No.6-7.
[0016] The present invention provides a medicine for preventing and / or treating heart disease, which comprises the above-mentioned circular RNA overexpression reagent and pharmaceutically acceptable excipients thereof.
[0017] The present invention provides a method for screening drugs for treating heart disease, the method comprising the steps of using a test drug to treat a receptor that lowly expresses the above-mentioned circ-CHACR and determining the expression level of circ-CHACR. When the expression level of circ-CHACR in the receptor is significantly increased after the receptor is treated with the test drug, the test drug can be determined to be a drug for treating heart disease; the heart disease includes one or more of myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction; the receptor includes one of blood, cardiac tissue and myocardial cells.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] The present invention provides an application of circular RNA or its overexpression reagent in the preparation of a product for preventing and / or treating heart disease. Studies have found that circular RNA overexpression can significantly inhibit myocardial cell hypertrophy, reduce pathological changes of myocardial hypertrophy, and significantly inhibit cardiac fibrosis. It can also significantly improve cardiac function and increase the heart's pumping capacity in a mouse myocardial hypertrophy model. By detecting the expression level of circular RNA, early diagnosis of myocardial hypertrophy or assessment of the risk of heart disease can be achieved, thereby improving the timeliness and accuracy of heart disease treatment. The drug for treating heart disease provided by the present invention is a new treatment for heart disease, providing a new option for the clinical treatment of heart disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 To analyze the abundance of circular RNA expression in pressure overload-induced cardiac hypertrophy by deep sequencing of circRNA;
[0021] Figure 2 The circular biological characteristics of circ-CHACR are identified in Figure 1. The lanes from left to right are the results of divergent PCR detection using cDNA as a template; the results of polymerase chain reaction detection using cDNA as a template; the results of divergent PCR detection using gDNA as a template; the results of polymerase chain reaction detection using gDNA as a template;
[0022] Figure 3 The expression levels of circ-CHACR were compared after in situ injection of circ-CHACR lentivirus and negative control virus into the mouse heart. a P < 0.05, n = 9, 8;
[0023] Figure 4Figure 2 is the effect of overexpression of circ-CHACR on myocardial hypertrophy induced by TAC surgery in mice, where A is a flow chart of overexpression of circ-CHACR inhibiting myocardial hypertrophy induced by TAC surgery in mice; B is a picture of heart tissue in different treatment groups; C is a comparison of heart weight / tibia length in different treatment groups; D is a comparison of lung weight / tibia length in different treatment groups; E is a graph showing the results of hematoxylin-eosin staining in different treatment groups; F is a graph showing the statistical results of myocardial cell surface area in different treatment groups; G is a graph showing the expression levels of ANP in different treatment groups detected by real-time fluorescence quantitative PCR; H is a graph showing the expression levels of BNP in different treatment groups detected by real-time fluorescence quantitative PCR; where Figure 4 The different colors of D, F, G, and H in the figure represent different groups, and the groups corresponding to different colors are consistent with those in C;
[0024] Figure 5 Comparison of the expression levels of circ-CHACR in H9c2 cardiomyocytes infected with circ-CHACR lentivirus and its negative control lentivirus. a P < 0.01, n = 3;
[0025] Figure 6 Figure 3 shows the effect of overexpression of circ-CHACR on angiotensin II-induced cardiomyocyte hypertrophy, where A is the result of F-actin staining in different treatment groups; B is the statistical result of cardiomyocyte surface area after treatment in different treatment groups; C is the comparison result of ANP expression level in different treatment groups; D is the comparison result of BNP expression level in different treatment groups; E is the protein / DNA ratio in different treatment groups, a P<0.05, b P < 0.01, n = 3;
[0026] Figure 7 Figure 3 shows the effect of overexpression of circ-CHACR on cardiac fibrosis induced by TAC surgery. A is the Sirius red staining of cardiac tissues in different treatment groups; B is the statistical analysis result of the fibrosis area of cardiac tissues in different treatment groups; C is the result of Acta1 expression level in different treatment groups. a P<0.05, b P<0.01, c P<0.0001, n=6, 6, 5, 5;
[0027] Figure 8 The effect of overexpression of circ-CHACR on TAC surgery-induced cardiac dysfunction, A is the statistical results of ejection fraction of the hearts in different treatment groups, B is the statistical results of short-axis shortening rate of the hearts in different treatment groups, a P<0.05, b P<0.01,c P<0.0001, n=6, 6, 5, 5;
[0028] Fig. 9 Real-time fluorescence quantitative PCR was used to detect the expression level of circ-CHACR for evaluating the risk of myocardial hypertrophy. A shows the expression level of circ-CHACR in the myocardial hypertrophy model induced by TAC surgery, and B shows the expression level of circ-CHACR in the myocardial hypertrophy model induced by angiotensin II. a P < 0.01, n = 6;
[0029] Fig.10 ROC curve analysis for circ-CHACR in cardiac tissue to predict and diagnose myocardial hypertrophy. DETAILED DESCRIPTION
[0030] The present invention constructs a heart disease (such as myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction) model through transverse aortic coarctation surgery (TAC surgery), uses a sham surgery group as a negative control, and then performs circRNA deep sequencing to screen out inhibitory factors of pressure overload heart disease, further analyzes and screens multiple circRNAs with downregulated expression levels and significant expression differences, and finally determines that the circular RNA is named circ-CHACR as a target for preventing and / or treating heart disease or for diagnosing or evaluating the risk of heart disease.
[0031] The present invention provides an application of a circular RNA or an overexpression agent thereof in preparing a product for preventing and / or treating heart disease. The nucleotide sequence of the circular RNA is shown in SEQ ID No. 1, and the circular RNA is named circ-CHACR.
[0032] In the application of the above-mentioned preparation of the product for preventing and / or treating heart disease, the heart disease includes one or more of myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction, wherein the myocardial hypertrophy is preferably myocardial hypertrophy induced by TAC surgery or myocardial cell hypertrophy induced by angiotensin II; the cardiac fibrosis is preferably cardiac fibrosis induced by TAC surgery; the cardiac dysfunction is preferably cardiac dysfunction induced by TAC surgery. The circular RNA of the present invention is circRNAmm9_circ_000673 or its ID in the circBase database is mmu_circ_0000996. The product includes an agent or a drug.
[0033] In the present invention, the circular RNA overexpression reagent includes a circ-CHACR overexpression lentivirus or a circ-CHACR overexpression vector. The circ-CHACR overexpression vector is a nucleotide sequence such as circ-CHACR DNA 5' end and 3' end shown in SEQ ID No. 16, respectively connected to the ALU flanking sequence 5'-ggtacgtactaatgactttttttttatacttcag-3' (SEQ ID No. 14) and 5'-gtaagaagcaaggaaaagaattaggctc-3' (SEQ ID No. 15), and then inserted into the backbone vector pLV3-CMV-MCS-Puro shuttle plasmid (purchased from Wuhan Miaoling Biotechnology Co., Ltd., Article No. P1268) to obtain, and the insertion site is the BamHI and NotI multiple cloning sites of the backbone vector. The circ-CHACR overexpression lentivirus is prepared by co-transfecting mammalian cells with the circ-CHACR overexpression vector and lentiviral packaging plasmids pGag / Pol, pRev and pVSV-G. The mammalian cells include HEK293T cells. The present invention does not specifically limit the sources of the lentiviral packaging plasmids pGag / Pol, pRev and pVSV-G, and products known in the art or commercially available can be used. The present invention provides a reagent for detecting the expression level of the above-mentioned circular RNA for use in the preparation of a product for diagnosing or assessing the risk of heart disease.
[0034] In the application of the above-mentioned preparation of a product for diagnosing or assessing the risk of heart disease, the product preferably includes a substance capable of binding to the cDNA of circular RNA, and the substance preferably includes a specific probe for detecting the cDNA of circular RNA. The heart disease preferably includes one or more of myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction. The product preferably includes one or more of a kit, a test strip, and a gene chip. The product or the reagent for detecting the expression level of the above-mentioned circular RNA preferably includes a primer set that can specifically amplify the cDNA of circular RNA. The nucleotide sequence of the primer set is preferably as shown in SEQ ID No.6-7. The present invention detects the expression level of the above-mentioned circular RNA. If the expression level of the circular RNA in the sample to be tested is significantly reduced compared with the healthy sample, it indicates a high risk of heart disease. The sample includes a blood sample, a heart tissue sample or a cardiomyocyte sample.
[0035] The present invention provides a medicine for preventing and / or treating heart disease, which comprises the above-mentioned circular RNA overexpression reagent and pharmaceutically acceptable excipients thereof.
[0036] In the present invention, the excipients include lentivirus, adenovirus and adeno-associated virus. The excipients may also be selected from one or more of chitosan, cholesterol, liposomes and nanoparticles. The drug is administered orally or by injection; the injection administration method is preferably selected from intravenous injection, intramuscular injection, intracoronary injection and myocardial injection. Circ-CHACR is packaged with appropriate carriers or excipients such as chitosan, cholesterol, liposomes, nanoparticles, etc. to form a drug combination, which is administered orally, intravenously, intramuscularly, intracoronary or directly myocardially to prevent or treat myocardial hypertrophy. The drug is administered orally or by injection; the injection administration method is preferably selected from intravenous injection, intramuscular injection, intracoronary injection and myocardial injection. Circ-CHACR is packaged with one or more of its pharmaceutically acceptable excipients such as chitosan, cholesterol, liposomes and nanoparticles to form a drug combination, which is administered orally, intravenously, intramuscularly, intracoronary or directly myocardially to prevent or treat heart disease (such as myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction).
[0037] The reagent for overexpressing circ-CHACR in the present invention can significantly inhibit heart diseases, such as myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction. Therefore, the drug that increases the expression level of circ-CHACR in patients can be used to treat heart diseases.
[0038] Based on this, the present invention provides a method for screening drugs for treating heart disease, the method comprising the steps of using a test drug to treat a receptor that lowly expresses the above-mentioned circ-CHACR and determining the expression level of circ-CHACR, when the receptor is treated with the test drug, the expression level of circ-CHACR in the receptor is significantly increased, and the test drug can be determined to be a drug for treating heart disease; the heart disease includes one or more of myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction; the receptor includes serum, heart tissue or myocardial cells.
[0039] In the above method, the method for detecting the expression level of circ-CHACR can be performed by real-time fluorescence quantitative PCR detection using a primer set as shown in SEQ ID No. 6 to 7. The PCR reaction system and PCR reaction procedure used in the method for detecting the expression level of circ-CHACR by real-time fluorescence quantitative PCR of the present invention are not particularly limited, and conventional methods in the art can be used.
[0040] In the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art.
[0041] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0042] In the following examples, DMEM high glucose cell culture medium (SH30243.01, Cytiva, USA); fetal bovine serum (SA101.01, Cellmax, China); trypsin (MA0232-1, Dalian Meilun Biotechnology Co., Ltd., China); double antibody (P1400, Beijing Solebow Technology Co., Ltd., China); angiotensin II (HY-13948, MCE, China); rhodamine-phalloidin dye (40734ES75, Sigma, USA); anti-fading agent containing DAPI (ZLI-9557, Beijing Zhongshan Jinqiao Biotechnology Co., Ltd., China); TRIzol reagent (10296010CN, Invitrogen, USA); circRNA reverse reagent (RR037A, Takara, Japan =This product was used as the research object. The product was used as the research object. The product was used as the research object. The product was used as the research object. The product was used as the research object. The product was used as the research object. The product was used as the research object.
[0043] Example 1
[0044] Selection and identification of circular RNA
[0045] In this example, transverse aortic constriction surgery (TAC surgery) was performed on 8-week-old C57BL / 6J mice to construct a myocardial hypertrophy model (TAC surgery group): the mice were anesthetized with 2% isoflurane, and a mouse ventilator was inserted orally. The tidal volume was set to 0.2 mL and the respiratory rate was set to 110 times / min. A longitudinal incision was made along the left edge of the sternum, the chest cavity was opened, the thymus was separated, the aortic arch was exposed, a 26G needle was padded at the aortic arch, and a knot was tied with 6-0 silk thread, and then the padded needle was removed. The sham operation group served as the negative control group, in which the sham operation group was the same as the TAC operation group except that the aortic arch was not ligated. Deep sequencing of circRNA was performed eight weeks after surgery.
[0046] Figure 1The results showed that a total of 826 circRNAs were detected in the mouse heart. Compared with the negative control group, in the myocardial hypertrophy model, there were 198 circRNAs with an upregulation fold greater than 2, 185 circRNAs with an upregulation fold greater than 2 and less than 10, 13 circRNAs with an upregulation fold greater than 10, 119 circRNAs with a downregulation fold greater than 2, 96 circRNAs with a downregulation fold greater than 2 and less than 10, and 23 circRNAs with a downregulation fold greater than 10. In order to find an inhibitory factor for pressure overload-induced myocardial hypertrophy, 23 circRNAs with expression levels down-regulated by more than 10 were further analyzed and screened. Finally, the circRNA mm9_circ_000673 with high conservation and significant expression differences among species was determined as the research object and named as myocardial hypertrophy-related circular RNA—circ-CHACR. The ID of circ-CHACR in the circBase database is mmu_circ_0000996, and the nucleotide sequence of circ-CHACR is: 5'-AAGCCCUGCAGAGGCCAGUGGCAUCUGACUUUGAGCCCCAGGGUCUCAGCG AAGCAGCUCGAUGGAACUCCAAGGAAAACCUUCUUGCUGGGCCCAGUGAAAAUGACCCCACCUUUUUGUGGCACUCUAUGAUUUUGUGGCCAGUGGAUAACACUCUCAGCAUCACUAAAGGUGAAAAGCUCCGGGUCUUGGGUUAUAAUCACAAUGGGGAAUGGUGUGAAGCCCAAACGAAAAAUGGCCAAGGAUGGGUCCCAAGCAACU ACAUCACCCCCGUCACAGCCUGGAGAAACAUUCCUGGUAUCAUGGCCCUGUAUCUCGGAAUGCUGCUGAGUAUCCUGAGCAGCGGAAUCAACGGCAGCUUCUUAGUGCGGGAGUGAGAGUAGCCCUGGCCAGAGAUCCAUCUCUCUGCGGUAUGAAGGGAGGGUGUACCACUACAGGAUCAACACUGCCUCUGAUGGCAAG-3'(SEQ ID No.1).
[0047] Genomic DNA was extracted from the heart tissue of normal 8-week-old C57BL / 6J mice, and total RNA from the heart of 8-week-old C57BL / 6J mice was extracted and reverse transcribed into total cDNA. Polymerase chain reaction (PCR) and divergence PCR experiments were performed using genomic gDNA and cDNA as templates, respectively, to identify the circular characteristics of circ-CHACR.
[0048] Among them, the primer sequences of polymerase chain reaction and divergent PCR for detecting the circular characteristics of circ-CHACR are shown in Table 1.
[0049] Table 1 Primer sequences for polymerase chain reaction (PCR) and divergent PCR
[0050] Primer Type Primer (5'-3') Polymer PCR forward primer GTGAAAAGCTCCGGGTCTTG(SEQ ID No.2) Polymer PCR reverse primer CTTCATACCGCAGCGAGATG(SEQ ID No.3) Divergent PCR forward primer ATCATGGCCCTGTATCTCGG(SEQ ID No.4) Divergent PCR reverse primer CCTGGGGCTCAAAGTCAGAT(SEQ ID No.5)
[0051] Figure 2 The results showed that both polymerase chain reaction and divergent PCR could amplify circ-CHACR fragments using cDNA as template, while only polymerase chain reaction could amplify circ-CHACR fragments using genomic gDNA as template. The above results indicate that circ-CHACR is circular.
[0052] Example 2
[0053] 1. Overexpression of circ-CHACR inhibits TAC surgery-induced myocardial hypertrophy in mice
[0054] 1.1 The construction method of circ-CHACR overexpression lentivirus includes: connecting the 5' and 3' ends of the DNA of circ-CHACR containing the nucleotide sequence as shown in SEQ ID No. 16 to the ALU flanking sequences 5'-ggtacgtactaatgactttttttttatacttcag-3' (SEQ ID No. 14) and 5'-gtaagaagcaaggaaaagaattaggctc-3' (SEQ ID No. 15), respectively, and cloning into the pLV3-CMV-MCS-Puro shuttle plasmid (purchased from Wuhan Miaoling Biotechnology Co., Ltd., item number P1268) at the BamHI and NotI restriction sites. Add 1.5 mL of serum-free DMEM to a sterile 5 mL centrifuge tube, and then add the pLV3-CMV-MCS-Puro shuttle plasmid containing the target sequence and three packaging plasmids pGag / Pol, pRev and pVSV-G and mix well. Take another sterile 5mL centrifuge tube, add 1.5mL serum-free DMEM, then add 300μL RNAi-Mate transfection reagent and mix well. After standing at room temperature for 5 minutes, mix the two tubes, stand at room temperature for 20-25 minutes, add dropwise to the HEK293 cell culture dish containing 8mL serum-free DMEM, gently shake the culture dish back and forth to mix the complex, and incubate in a 37℃ 5% CO2 incubator for 4-6 hours. Aspirate the transfection solution and add 18mL DMEM culture solution containing 10% FBS. Continue to culture at 37℃ 5% CO2 for 72 hours. Finally, collect the cell supernatant rich in lentiviral particles and concentrate it. The concentrated virus reaches 10 8The above titers were used to obtain circ-CHACR overexpression lentivirus.
[0055] The nucleotide sequence of circ-CHACR DNA is as follows: 5'-AAGCCCTGCAGAGGCCAGTGGCATCTGACTTTGAGCCCCAGGGTCTCAGCGA AGCAGCTCGATGGAACTCCAAGGAAAACCTTCTTGCTGGGCCCAGTGAAAATGACCCCAACCTTTTTGTGGCACTCTATGATTTTGTGGCCAGTGGAGATAACACTCTCAGCATCACTAAAGGTGAAAAGCTCCGGGTCTTGGGTTATAATCACAATGGGGAATGGTGTGAAGCCCAAACGAAAAATGGCCAAGGATGGGTCCCAAGCAACTACATC ACCCCCGTCAACAGCCTGGAGAAACATTCCTGGTATCATGGCCCTGTATCTCGGAATGCTGCTGAGTATCTGCTGAGCAGCGGAATCAACGGCAGCTTCTAGTGCGGGAGAGTGAGAGTAGCCCTGGCCAGAGATCCATCTCGCTGCGGTATGAAGGGAGGGTGTACCACTACAGGATCAACACTGCCTCTGATGGCAAG-3' (SEQ ID No. 16).
[0056] At the same time, construct a negative control lentivirus: add 1.5mL of serum-free DMEM to a sterile 5mL centrifuge tube, then add the pLV3-CMV-MCS-Puro shuttle plasmid without any target sequence and three packaging plasmids pGag / Pol, pRev and pVSV-G and mix well. Take another sterile 5mL centrifuge tube, add 1.5mL of serum-free DMEM, then add 300μL of RNAi-Mate transfection reagent and mix well. After standing at room temperature for 5 minutes, mix the two tubes, stand at room temperature for 20-25 minutes, add dropwise to the HEK293 cell culture dish containing 8mL of serum-free DMEM, gently shake the culture dish back and forth to mix the complex, and incubate in a 37℃ 5% CO2 incubator for 4-6 hours. Aspirate the transfection solution and add 18mL of DMEM culture solution containing 10% FBS. Continue to culture at 37℃ 5% CO2 for 72 hours. Finally, the cell supernatant rich in lentiviral particles was collected and concentrated to a concentration of 10 8 The above titers were used to obtain negative control lentivirus.
[0057] 1.2 This Example In order to detect the role of circ-CHACR in TAC surgery-induced myocardial hypertrophy in mice, the circ-CHACR overexpression lentivirus (circ-CHACR overexpression group) or its negative control lentivirus (negative control group) was injected in situ into the heart: On a sterile operating table, mice were anesthetized with 2% isoflurane, and a mouse ventilator was inserted orally. The tidal volume was set to 0.2 mL and the respiratory rate was set to 110 times / min. A skin incision of approximately 0.5 cm was made along the line connecting the xiphoid process and the axilla, and the pectoralis major and minor muscles were bluntly separated. The thoracotomy was performed on the third rib on the left side to expose the mouse heart. Use a Hamilton syringe to inject 40 μL of a titer of 10 6 The circ-CHACR overexpression lentivirus or its negative control lentivirus constructed in part 1.1 was injected into the cardiac myocardium at 5 points, 8 μL at each point, and each group was injected once. The circ-CHACR overexpression group was divided into 9 parallels, and the negative control group was divided into 8 parallels. Real-time fluorescence quantitative PCR was used to detect the expression level of circ-CHACR one week after in situ injection of circ-CHACR overexpression lentivirus or its negative control lentivirus in the heart.
[0058] Among them, the method for detecting the expression level of circ-CHACR by real-time fluorescence quantitative PCR is as follows:
[0059] (1) Total RNA was extracted from mouse heart tissue using TRIzol reagent, and the total RNA concentration and purity were detected.
[0060] (2) circRNA was synthesized into cDNA using a reverse transcription kit (TAKARA, RR037a).
[0061] Reverse transcription system of circ-CHACR:
[0062]
[0063] Program: 37℃15min; 85℃5sec; 4℃,∞.
[0064] Among them, the random primers are the random primers in the circRNA reverse transcription kit (TAKARA, RR037a).
[0065] (3) The cDNA of circ-CHACR was amplified using the SYBR Green PCR kit (Beijing PolyMei Biotechnology Co., Ltd., MF797), and its expression level was detected on Applied Biosystems Quant Studio 3.
[0066] PCR amplification reaction system:
[0067]
[0068] Among them, circ-CHACR-F: CATCTCGCTGCGGTATGAAG (SEQ ID No. 6); circ-CHACR-R: CCTGGGGCTCAAAGTCAGAT (SEQ ID No. 7).
[0069] PCR amplification reaction procedure:
[0070] Step 1: 95℃30s;
[0071] Step 2: 95°C for 5s, 60°C for 34s, for a total of 40 cycles.
[0072] GAPDH was used as an internal reference.
[0073] Figure 3 The results showed that the expression level of circ-CHACR in the circ-CHACR overexpression group was significantly increased compared with that in the circ-CHACR negative control group, indicating that circ-CHACR was successfully overexpressed in vivo and can be used for subsequent experimental studies.
[0074] In order to further detect whether circ-CHACR is involved in myocardial hypertrophy induced by TAC surgery, the experiment was divided into sham operation group, TAC operation group, circ-CHACR overexpression + TAC operation group and circ-CHACR negative control + TAC operation group in this example, wherein the sham operation group, TAC operation group, circ-CHACR overexpression + TAC operation group and circ-CHACR negative control + TAC operation group were 6, 6, 5, and 5 parallel experiments, respectively. Among them, the treatment methods of the sham operation group and the TAC operation group refer to Example 1. The treatment methods of the circ-CHACR overexpression + TAC operation group and the circ-CHACR negative control + TAC operation group are respectively: the method of injecting circ-CHACR overexpression lentivirus or its negative control lentivirus described in Section 1.2 of this example is adopted, and the circ-CHACR overexpression lentivirus or its negative control lentivirus is injected in situ in the mouse heart for 1 week, and then the TAC operation is performed according to the TAC operation method of Example 1. Eight weeks after surgery, the following indicators related to myocardial hypertrophy were detected: cardiac tissue morphology, heart mass / tibia length ratio and lung mass / tibia length ratio, hematoxylin-eosin staining to detect the surface area of myocardial cells, and real-time fluorescence quantitative PCR to detect the expression levels of hypertrophy marker genes (atrial natriuretic peptide ANP and brain natriuretic peptide BNP).
[0075] After anesthetizing mice with an overdose of 5% isoflurane, mice in each group were euthanized by cervical dislocation, and the heart, lungs, and tibia were separated. The heart was photographed, the heart and lung masses were weighed, the tibia length was measured, and the heart mass / tibia length ratio and lung mass / tibia length ratio were calculated.
[0076] The method for detecting the surface area of myocardial cells by hematoxylin-eosin staining includes: fixing the isolated heart with 40g / L paraformaldehyde, dehydrating and transparentizing, embedding in paraffin, and slicing with a thickness of 4μm. Before staining, the tissue sections are first dewaxed to water, and the staining results are observed and photographed under a microscope after sealing according to the hematoxylin-eosin staining kit, and the cell cross-sectional area is analyzed using the image analysis software Image J as an indicator of myocardial hypertrophy.
[0077] The method for detecting the expression level of hypertrophy marker genes by fluorescence quantitative PCR is referred to Section 1.2 of this embodiment, wherein the upstream primer of atrial natriuretic peptide ANP is TAGGAGACAGTGACGGACAA (SEQ ID No.8), and the downstream primer of atrial natriuretic peptide ANP is GAAGAAGCCCAGGGTGAT (SEQ ID No.9); the upstream primer of brain natriuretic peptide BNP is GACGGGCTGAGGGT (SEQ ID No.10), and the downstream primer of brain natriuretic peptide BNP is CGATCCGGTCTATCTTCTGC (SEQ ID No.11). mRNA is reversed into cDNA using the full gold reverse transcription kit (AU341). Reverse transcription system for detecting hypertrophy indicators ANP and BNP:
[0078]
[0079] Program: 50℃5min; 85℃2min; 4℃, ∞.
[0080] Figure 4 The results showed that compared with the sham operation group, the heart volume in the TAC operation group was significantly increased, the heart weight / tibia length ratio and lung weight / tibia length ratio increased, the cardiomyocyte surface area increased, and the expression levels of hypertrophy marker genes atrial natriuretic peptide and brain natriuretic peptide were significantly increased. The above results show that the mouse cardiac hypertrophy model induced by transverse aortic constriction surgery (TAC surgery) for 8 weeks was successfully established. Compared with the circ-CHACR negative control + TAC operation group, circ-CHACR overexpression significantly inhibited the increase of heart volume, heart weight / tibia length ratio and lung weight / tibia length ratio, cardiomyocyte surface area, and hypertrophy marker genes atrial natriuretic peptide and brain natriuretic peptide induced by TAC surgery. The above results show that overexpression of circ-CHACR significantly inhibited TAC surgery-induced cardiac hypertrophy in mice.
[0081] 2. Overexpression of circ-CHACR inhibits angiotensin II-induced cardiomyocyte hypertrophy
[0082] This example aims to detect the role of circ-CHACR in angiotensin II (Ang II)-induced cardiomyocyte hypertrophy model.
[0083] H9c2 cells in the logarithmic growth phase were obtained and digested with trypsin and then cultured at a volume of 1×10 5 The concentration of 500 μL was inoculated in a 24-well plate pre-laid with a 1 cm × 1 cm cover glass, and cultured in a cell culture incubator at 37 ° C and 5% CO2 for 24 h. After 72 h of treatment with circ-CHACR overexpression lentivirus (circ-CHACR overexpression group) and its virus infection multiplicity MOI = 50 negative control lentivirus (circ-CHACR negative control group), the expression level of circ-CHACR was detected by real-time fluorescence quantitative PCR described in Section 1.2, with 3 parallels in each group. Among them, the control group did not receive any treatment.
[0084] Figure 5 The results showed that the expression level of circ-CHACR in the circ-CHACR overexpression group was significantly increased compared with that in the circ-CHACR negative control group, indicating that circ-CHACR was successfully overexpressed in vitro and can be used for subsequent experimental studies.
[0085] The experiment was divided into control group, AngⅡ treatment group, circ-CHACR overexpression + AngⅡ treatment group and circ-CHACR negative control + AngⅡ treatment group, with 3 parallel experiments in each group. In the AngⅡ treatment group, H9c2 cells in the logarithmic growth phase were obtained and digested with trypsin and then cultured at 1×10 5The cells were inoculated with a concentration of 500 μL in a 24-well plate pre-coated with a 1 cm × 1 cm coverslip. After culturing in a cell culture incubator at 37 ° C and a volume fraction of 5% CO2 for 24 hours, 1 μmol / L angiotensin II was added to the H9c2 cells for 24 hours. The control group was treated with PBS for 24 hours in the above H9c2 cells. The circ-CHACR overexpression + AngⅡ treatment group and the circ-CHACR negative control + AngⅡ treatment group were respectively added to the above H9c2 cells with a virus infection multiplicity MOI = 50 circ-CHACR overexpression lentivirus or its virus infection multiplicity MOI = 50 negative control lentivirus for 72 hours. When the cell confluence reached about 70%, 1 μmol / L angiotensin II was added for 24 hours to induce cardiomyocyte hypertrophy. Detection of myocardial hypertrophy-related indicators: F-actin staining was used to measure the cell surface area and protein / DNA ratio, and real-time fluorescence quantitative PCR was performed according to the above method to detect the expression levels of hypertrophy marker genes (atrial natriuretic peptide ANP and brain natriuretic peptide BNP).
[0086] F-actin staining method was used to measure the cell surface area: the cells were washed twice with PBS, fixed with 40 g / L paraformaldehyde for 10 min, stained with 100 nmol / L rhodamine-phalloidin dye (TRITC) for 30 min in the dark, the staining solution was discarded, the cells were washed three times with PBS for 5 min each time, and sealed with an anti-fade agent containing DAPI. The cardiomyocytes were observed under a fluorescence microscope and photographed, and the cell surface area was counted using Image J software.
[0087] Protein / DNA ratio determination: cells were washed twice with pre-cooled PBS, 100 μL of cell lysis buffer (the cell lysis buffer was 150 mmol / L sodium chloride, 15 mmol / L sodium citrate and 0.25% SDS; pH = 7.0) was added, cells were collected by cell scraping, and immediately frozen at -20°C. After thawing, vortex mixing was performed, 1 μL of sample was taken to measure protein content by BCA method, DNA content was detected by DNA quantitative kit, and protein / DNA ratio was calculated.
[0088] Figure 6The results showed that compared with the control group, the cell surface area in the angiotensin II-treated group increased significantly, the expression levels of hypertrophy marker genes such as atrial natriuretic peptide and brain natriuretic peptide increased, and the protein / DNA ratio increased. The above results show that the angiotensin II-induced cardiomyocyte hypertrophy model in vitro was successfully constructed. After adding circ-CHACR overexpression lentivirus, the angiotensin II-induced cardiomyocyte hypertrophy effect was significantly alleviated compared with the circ-CHACR negative control + AngⅡ treatment group, which was specifically manifested in: the cell surface area decreased after F-actin staining, the expression levels of hypertrophy marker genes such as atrial natriuretic peptide and brain natriuretic peptide decreased, and the protein / DNA ratio decreased. The above results show that overexpression of circ-CHACR significantly inhibited angiotensin II-induced cardiomyocyte hypertrophy.
[0089] Example 3
[0090] Overexpression of circ-CHACR inhibits TAC surgery-induced cardiac fibrosis
[0091] The experiment was divided into a sham operation group, a TAC operation group, a circ-CHACR overexpression + TAC operation group, and a circ-CHACR negative control + TAC operation group. The sham operation group, the TAC operation group, the circ-CHACR overexpression + TAC operation group, and the circ-CHACR negative control + TAC operation group were 6, 6, 5, and 5 parallel experiments, respectively. Among them, the treatment methods of the sham operation group and the TAC operation group refer to Example 1. The treatment methods of the circ-CHACR overexpression + TAC operation group and the circ-CHACR negative control + TAC operation group were: the injection of circ-CHACR overexpression lentivirus or its negative control lentivirus method described in Section 1.2 of Example 2 was used, and the circ-CHACR overexpression lentivirus or its negative control lentivirus was injected into the mouse heart in situ for 1 week, and then the TAC operation was performed according to the TAC operation method of Example 1. Eight weeks after the operation, the fibrosis area of the heart tissue was detected by Sirius red staining and the expression level of fibrosis-related genes was detected by real-time fluorescence quantitative PCR. At the same time, the image analysis software Image J was used to analyze the fibrosis area as an indicator of cardiac fibrosis. The expression levels of fibrosis-related genes were detected by real-time fluorescence quantitative PCR according to the method of Example 2, wherein the related gene was Acta1, the upstream primer of Acta1 was GCTGTGTTCCCATCCATCGT (SEQ ID No. 12); the downstream primer of Acta1 was GCAGGCACGTTGAAGGTCTC (SEQ ID No. 13).
[0092] Figure 7 The results showed that overexpression of circ-CHACR significantly inhibited TAC surgery-induced cardiac fibrosis in mice.
[0093] Example 4
[0094] Overexpression of circ-CHACR improves TAC surgery-induced cardiac dysfunction
[0095] The experiment was divided into a sham operation group, a TAC operation group, a circ-CHACR overexpression + TAC operation group, and a circ-CHACR negative control + TAC operation group. The sham operation group, the TAC operation group, the circ-CHACR overexpression + TAC operation group, and the circ-CHACR negative control + TAC operation group were 6, 6, 5, and 5 parallel experiments, respectively. Among them, the treatment methods of the sham operation group and the TAC operation group refer to Example 1. The treatment methods of the circ-CHACR overexpression + TAC operation group and the circ-CHACR negative control + TAC operation group were: the injection method of circ-CHACR overexpression lentivirus or its negative control lentivirus described in Section 1.2 of Example 2 was used, and the circ-CHACR overexpression lentivirus or its negative control lentivirus was injected in situ into the mouse heart for 1 week, and then the TAC operation was performed according to the TAC operation method of Example 1. The cardiac function of the mice was detected by echocardiography 8 weeks after surgery.
[0096] Echocardiography to detect cardiac function of mice: After anesthetizing mice with 2% isoflurane, fix the mice in supine position on the animal operation platform, place the mouth and nose of the mice in the anesthesia mask, and maintain the anesthesia effect with 1.5% isoflurane. Apply an appropriate amount of coupling agent to the chest area after skin preparation, obtain M-mode images of the long axis of the left ventricle, record at least 3 cardiac cycles continuously, and record the ejection fraction and short axis shortening rate.
[0097] Figure 8 The results showed that when the circ-CHACR overexpression lentivirus was injected in situ into the heart, circ-CHACR overexpression significantly inhibited the decrease in ejection fraction and short-axis shortening rate compared with the negative control group, indicating that overexpression of circ-CHACR significantly improved TAC surgery-induced cardiac dysfunction.
[0098] Example 5
[0099] A primer set for detecting myocardial hypertrophy, wherein the primer set is a primer set for detecting the expression level of circ-CHACR, wherein circ-CHACR-F: CATCTCGCTGCGGTATGAAG (SEQ ID No. 6); circ-CHACR-R: CCTGGGGCTCAAAGTCAGAT (SEQ ID No. 7).
[0100] Example 6
[0101] A method for evaluating the risk of myocardial hypertrophy, cardiac fibrosis or cardiac dysfunction using the primer set of Example 5, wherein the expression level of circ-CHACR in the test sample and the negative control sample is detected by real-time fluorescence quantitative PCR using the method of Section 1.2 of Example 2, wherein the test sample and the negative control sample are taken from serum in the blood, and the negative control sample is serum in the blood of a healthy person.
[0102] The evaluation criteria are: if the expression level of circ-CHACR in the test sample is significantly downregulated compared with the negative control sample, it indicates a high risk of myocardial hypertrophy, cardiac fibrosis or cardiac dysfunction.
[0103] Example 7
[0104] A method for evaluating the risk of myocardial hypertrophy using the primer set of Example 5
[0105] 1. In this example, transverse aortic constriction surgery was performed on C57BL / 6J mice to expose the aortic arch, and a 26G needle was placed at the aortic arch, tied with a 6-0 silk thread, and then the needle was removed (TAC surgery group). The sham surgery group was operated in the same way as the TAC surgery group except that the aortic arch was not ligated. Eight weeks after surgery, myocardial hypertrophy-related indicators were detected. Six parallel groups were included in each group.
[0106] Figure 4 The results showed that the mouse myocardial hypertrophy model induced by transverse aortic constriction surgery 8 weeks ago was successfully established.
[0107] In this example, heart tissues of mice were obtained 8 weeks after transverse aortic constriction surgery, and the expression level of circ-CHACR was detected by real-time fluorescence quantitative PCR using the method in Section 1.2 of Example 2.
[0108] Fig. 9 The results in Figure A showed that the expression level of circ-CHACR in the heart tissue of mice in the TAC surgery group was significantly decreased compared with that in the sham surgery group.
[0109] 2. Take H9c2 cells in the logarithmic growth phase, digest them with trypsin, and add 1×10 5 The concentration of cells / mL was 500 μL, and the cells were inoculated in a 24-well plate with a 1 cm×1 cm cover glass pre-coated. After culturing for 24 hours in a cell culture incubator at 37°C and 5% CO2, 1 μmol / L angiotensin II was added to the H9c2 cells for 24 hours. The control group was treated with PBS in the above H9c2 cells for 24 hours. Each group had 6 parallels.
[0110] Figure 6The results showed that compared with the control group, the cell surface area in the angiotensin II-treated group was significantly increased, the expression levels of hypertrophy marker genes such as atrial natriuretic peptide and brain natriuretic peptide increased, and the protein / DNA ratio increased. The above results showed that the angiotensin II-induced cardiomyocyte hypertrophy model in vitro was successfully established.
[0111] In this example, 1 μmol / L angiotensin II was added to H9c2 cells for 24 h, and then the expression level of circ-CHACR was detected by real-time fluorescence quantitative PCR using the method of Section 1.2 of Example 2.
[0112] Fig. 9 The results in Figure B showed that compared with the control group, the expression level of circ-CHACR was significantly downregulated after 24 hours of angiotensin II treatment.
[0113] Fig.10 The results of the ROC curve showed that the area under the curve of circ-CHACR was 0.9722, which had a high predictive value for the occurrence of myocardial hypertrophy, indicating that circ-CHACR has a clear diagnostic value for myocardial hypertrophy.
[0114] In this example, heart tissues of mice were obtained 8 weeks after transverse aortic constriction surgery or sham surgery, and the diagnostic efficacy of circ-CHACR as a biomarker for predicting myocardial hypertrophy was evaluated by ROC curve.
[0115] It can be seen that the expression level of circ-CHACR was significantly downregulated in both the TAC surgery-induced mouse myocardial hypertrophy model and the angiotensin II-induced cardiomyocyte hypertrophy model, indicating that the expression level of circ-CHACR can be used to assess the risk of myocardial hypertrophy.
[0116] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Use of a circular RNA or an overexpression agent thereof in the preparation of a product for preventing and / or treating heart disease, characterized in that: The nucleotide sequence of the circular RNA is shown in SEQ ID No. 1, and the circular RNA is named circ-CHACR.
2. The use according to claim 1, characterized in that: The heart disease includes one or more of myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction; the circular RNA overexpression reagent includes circ-CHACR overexpression lentivirus or circ-CHACR overexpression vector.
3. Use of a reagent for detecting the expression level of the circular RNA described in claim 1 in the preparation of a product for diagnosing or assessing the risk of heart disease.
4. The use according to claim 3, characterized in that: The product includes a substance capable of binding to cDNA of circular RNA; the heart disease includes one or more of myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction.
5. The use according to claim 3, characterized in that: The product includes one or more of a test kit, a test strip, and a gene chip.
6. The use according to claim 3, characterized in that: The product includes a primer set capable of specifically amplifying cDNA of circular RNA.
7. The use according to claim 4, characterized in that: The substance includes a cDNA-specific probe for detecting circular RNA.
8. The use according to claim 6, characterized in that: The nucleotide sequences of the primer set are shown in SEQ ID No. 6-7.
9. A drug for preventing and / or treating heart disease, comprising the circular RNA or its overexpression agent as described in claim 1 or 2 and a pharmaceutically acceptable excipient thereof.
10. A method for screening drugs for treating heart disease, characterized in that: The method comprises the steps of using a test drug to treat a receptor that under-expresses the circ-CHACR of claim 1 and determining the expression level of circ-CHACR. When the expression level of circ-CHACR in the receptor is significantly increased after the receptor is treated with the test drug, the test drug can be determined to be a drug for treating heart disease; the heart disease comprises one or more of myocardial hypertrophy, cardiac fibrosis and cardiac dysfunction; the receptor comprises one of blood, cardiac tissue and myocardial cells.
